Clinically validated approaches to the treatment of autoimmune diseases

Expert Opinion on Investigational Drugs

Volumn 19, Issue 2, 2010, Pages 195-213

  Carter, Percy H ^a   Zhao, Qihong ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Autoimmune disease; Crohn's disease; Multiple sclerosis; Psoriasis; Randomized clinical trial; Rheumatoid arthritis; Systemic lupus erythematosus

Indexed keywords

ABATACEPT; ADALIMUMAB; ALEFACEPT; ALEMTUZUMAB; BETA1A INTERFERON; CERTOLIZUMAB PEGOL; CYCLOSPORIN; EFALIZUMAB; ETANERCEPT; FINGOLIMOD; GLATIRAMER; GOLIMUMAB; INFLIXIMAB; INTERFERON BETA SERINE; METHOTREXATE; NATALIZUMAB; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; SIMPONI; TOCILIZUMAB; UNCLASSIFIED DRUG; USTEKINUMAB; XANNELIM;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CROHN DISEASE; HUMAN; MULTIPLE SCLEROSIS; PATHOGENESIS; PSORIASIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; TUBERCULOSIS;

ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; AUTOIMMUNE DISEASES; CLINICAL TRIALS AS TOPIC; CROHN DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFECTION; LUPUS ERYTHEMATOSUS, SYSTEMIC; MODELS, IMMUNOLOGICAL; MULTIPLE SCLEROSIS; PSORIASIS; RECOMBINANT PROTEINS;

EID: 74549167854     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543780903418452     Document Type: Review

References (146)

1. Report of the Autoimmune Diseases Coordinating Committee, National Institutes of Health. October 2000. Available from: http://www3.niaid.nih. gov/topics/autoimmune/PDF/adccrev.pdf [Last accessed 19 December 2009]
2. Progress in Autoimmune Disease Research, Report to Congress. The Autoimmune Diseases Coordinating Committee, National Institutes of Health. March 2005. Available from: http://www3.niaid.nih.gov/topics/ autoimmune/PDF/ ADCCFinal.pdf [Last accessed 19 December 2009]
3. Jacobsen DL, Gange SJ, Rose NR, Graham NMH. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin Immun Immunopathol 1997;84:223-243
4. Libby P. Role of inflammation in atherosclerosis associated with rheumatoid arthritis. Am J Med 2008;121(10 Suppl 1):S21-31
5. Hyrich KL. Patients with suspected rheumatoid arthritis should be referred early to rheumatology. BMJ 2008;336:215-216
6. Felson DT. Whither the ACR20? J Rheumatol 2004;31:835-837
7. Felson DT, Furst DE, Boers M. Rationale and strategies for reevaluating the ACR20. J Rheumatol 2007;34:1184-1187
8. Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26-37
9. Kay J, Matteson EL, Dasgupta B, et al. Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum 2008;58:964-975
10. Choy EH, Hazleman B, Smith M, et al. Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial. Rheumatology (Oxf) 2002;41:1133-1137
11. Pappas DA, Bathan JM, Hanicq D, et al. Golimumab. Nat Rev Drug Discov 2009;8:695-696
12. Genovese MC, Cohen S, Moreland L, et al. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum 2004;50:1412-1419
13. Jones G, Sebba A, Gu J, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis 2010;69:88-96
14. Stoll JG, Yasothan U. Rheumatoid arthritis market. Nat Rev Drug Discov 2009;8:693-694
15. Cohen SB, Dore RK, Lane NE, et al. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis. Arthritis Rheum 2008;58:1299-1309
16. Dore RK, Cohen SB, Lane NE, et al. Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates. Ann Rheum Dis 2009. [Epub ahead of print]; PubMed PMID:19734132; doi 10.1136/ard.2009.112920
17. Ostör AJ. Abatacept: a T-cell co-stimulation modulator for the treatment of rheumatoid arthritis. Clin Rheumatol 2008;27:1343-1353
18. Rokosz LL, Beasley JR, Carroll CD, et al. Kinase inhibitors as drugs for chronic inflammatory and immunological diseases: progress and challenges. Expert Opin Ther Targets 2008;12:883-903
19. Cohen SB, Cheng TT, Chindalore V, et al. Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis. Arthritis Rheum 2009;60:335-344
20. Damjanov N, Kauffman RS, Spencer-Green GT. Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies. Arthritis Rheum 2009;60:1232-1241
21. Weinblatt ME, Kavanaugh A, Burgos-Vargas R, et al. Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial. Arthritis Rheum 2008;58:3309-3318
22. Coombs JH, Bloom BJ, Breedveld FC, et al. Improved pain, physical functioning, and health status in rheumatoid arthritis patients treated with CP-690,550, an orally active Janus Kinase (JAK) inhibitor: results from a randomized, double-blind, placebo-controlled trial. Ann Rheum Dis 2009. [Epub 8 July 2009]; PMID 19587388, doi 10.1136/ard.2009.108159
23. Kremer JM, Bloom BJ, Breedveld FC, et al. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase Iia trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum 2009;60:1895-1905
24. Gladman DD. Targeted therapies for psoriatic arthritis. Nat Rev Rheumatol 2009;5:241-242
25. Traub M, Marshall K. Psoriasis-pathophysiology, conventional, and alternative approaches to treatment. Altern Med Rev 2007;12:319-330
26. Jacobsen CC, Kimball AB. Rethinking the psoriasis and severity index: the impact of area should be increased. Br J Dermatol 2004;151:381-387
27. Boker A, Kimball AB, Rolz-Cruz G. Biologicals in the treatment of psoriasis. Curr Opin Investig Drugs 2007;8:939-946
28. Nickoloff BJ, Qin J-Z, Nestle FO. Immunopathogenesis of psoriasis. Clin Rev Allerg Immunol 2007;3:45-56
29. Papp K, Bissonnette R, Rosoph L, et al. Efficacy of ISA247 in plaque psoriasis: a randomised, multicentre, double-blind, placebo-controlled phase III study. Lancet 2008;371:1337-1342
30. Lopez-Diego RS, Weiner HL. Novel therapeutic strategies for multiple sclerosis-a multifaceted adversary. Nat Rev Drug Discov 2008;7:909-925
31. Lublin F. Multiple sclerosis trial designs for the 21st century: building on recent lessons. J Neurol 2005;252:(Suppl 5):v46-53
32. Wiendl H, Hohlfeld R. Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials. Biodrugs 2002;16:183-200
33. De Jager PL, Hafler DA. New therapeutic approaches for multiple sclerosis. Annu Rev Med 2007;58:417-432
34. Segal BS, Constantinescu CS, Raychaudhuri A, et al. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study. Lancet Neurol 2008;7:796-804
35. Blanchette F, Neuhaus O. Glatiramer acetate: evidence for a dual mechanism of action. J Neurol 2008;255:(Suppl 1):26-36
36. Gribben JG, Hallek M. Rediscovering alemtuzuman: current and emerging therapeutic roles. Br J Haematol 2009;144;818-831
37. Hirst CL, Pace A, Pickersgill TP, et al. Campath 1-H treatment in patients with aggressive relapsing remitting multiple sclerosis. J Neurol 2008;255:231-238
38. DeAngelis T, Lublin F. Multiple sclerosis: new treatment trials and emerging therapeutic targets. Curr Opin Neurol 2008;21:261-271
39. Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008;358:676-688
40. Rose JW, Burns JB, Bjorklund J, et al. Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results. Neurology 2007;69:785-789
41. Gasperini C, Cefaro LA, Borriello G, et al. Emerging oral drugs for multiple sclerosis. Exp Opin Emerg Drugs 2008;13:465-477
42. O'Connor P, Comi G, Montalban X, et al. Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study. Neurology 2009;72:73-79
43. Pineton de Chambrun G, Colombel JF, Poulain D, Darfeuille-Michaud A. Pathogenic agents in inflammatory bowel diseases. Curr Opin Gastroenterol 2008;24:440-447
44. Peyrin-Biroulet L, Desreumaux P, Sandborn WJ, Colombel JF. Crohn's disease: beyond antagonists of tumour necrosis factor. Lancet 2008;372:67-81
45. Cummings JR, Keshav S, Travis SP. Medical management of Crohn's disease. BMJ 2008;336:1062-1066
46. Thia KT, Sandborn WJ, Lewis JD, et al. Defining the optimal response criteria for the Crohn's disease activity index for induction studies in patients with mildly to moderately active Crohn's disease. Am J Gastroenterol 2008;103:3123-3131
47. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004;350:876-885
48. Lichtenstein GR, Yan S, Bala M, et al. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology 2005;128:862-869
49. Rahman T, Isenberg DA. Systemic lupus erythematosus. N Engl J Med 2008;358:929-939
50. Harley JB, Alarcón-Riquelme ME, Criswell LA, et al; International Consortium for Systemic Lupus Erythematosus Genetics (SLEGEN); Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci. Nat Genet 2008;40:204-210
51. Appel GB, Contreras G, Dooley MA, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 2009;20:1103-1112
52. Eisenberg R. Why can't we find a new treatment for SLE? J Autoimmunity 2009;32;223-230
53. Monneaux F, Muller S. Molecular therapies for systemic lupus erythematosus: clinical trials and future prospects. Arthritis Res Ther 2009;11:234
54. Cardiel MH, Tumlin JA, Furie RA, et al. Abetimus sodium for renal flare in systemic lupus erythematosus: results of a randomized, controlled phase III trial. Arthritis Rheum 2008;58:2470-2480
55. Merrill JT, Buyon JP. Connective tissue diseases: what does the death of Riquent hold for the future of SLE? Nat Rev Rheumatol 2009;5:306-307
56. Coca A, Sanz I. B cell depletion in lupus and Sjögren's syndrome: an update. Curr Opin Rheumatol 2009;21:483-488
57. Ramos-Casals M, D́iaz-Lagares C, Khamashta MA. Rituximab and lupus: good in real life, bad in controlled trials. Comment on the article by Lu, et al. Arthritis Rheum 2009;61:1281-1282
58. Wallace DJ, Stohl W, Furie RA, et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum 2009;61:1168-1178
59. Furie RA, Petri MA, Wallace DJ, et al. Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum 2009;61:1143-1151
60. Niewold TB, Hua J, Lehman TJ, et al. High serum IFN-alpha activity is a heritable risk factor for systemic lupus erythematosus. Genes Immun 2007;8:492-502
61. Baechler EC, Batliwalla FM, Karypis G, et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA 2003;100:2610-2615
62. Niewold TB. Interferon alpha-induced lupus: proof of principle. J Clin Rheumatol 2008;14:131-132
63. Yao Y, Richman L, Higgs BW, et al. Neutralization of interferon-alpha/ beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus. Arthritis Rheum 2009;60:1785-1796
64. Strand V, Kimberly R, Isaacs JD. Biologic therapies in rheumatology: lessons learned, future directions. Nat Rev Drug Discov 2007;6:75-92
65. Weinblatt ME, Maddison PJ, Bulpitt KJ, et al. CAMPATH-1H, a humanized monoclonal antibody, in refractory rheumatoid arthritis. An intravenous dose-escalation study. Arthritis Rheum 1995:38:1589-1594
66. Wendling D, Racadot E, Wijdenes J, et al. A randomized, double blind, placebo controlled multicenter trial of murine anti-CD4 monoclonal antibody therapy in rheumatoid arthritis. J Rheumatol 1998;25:1457-1461
67. Moreland LW, Pratt PW, Mayes MD, et al. Double-blind, placebo-controlled multicenter trial using chimeric monoclonal anti-CD4 antibody, cM-T412, in rheumatoid arthritis patients receiving concomitant methotrexate. Arthritis Rheum 1995;38:1581-1588
68. van Oosten BW, Barkhof F, Truyen L, et al. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 1996;47:1531-1534
69. Lenercept Multiple Sclerosis Study Group and University of British Columbia MS/ MRI Analysis Group. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology 1999;53:457-465
70. Hamon MA, Nicolas G, Deviere F, et al. Demyelinating neuropathy during anti-TNF alpha treatment with a review of the literature. Rev Neurol (Paris) 2007;163:1232-1235
71. Selmaj K, Raine CS, Cross AH. Anti-tumor necrosis factor therapy abrogates autoimmune demyelination. Ann Neurol 1991;30:694-700
72. Glabinski AR, Bielecki B, Kawczak JA, et al. Treatment with soluble tumor necrosis factor receptor (sTNFR):Fc/p80 fusion protein ameliorates relapsing-remitting experimental autoimmune encephalomyelitis and decreases chemokine expression. Autoimmunity 2004;37:465-471
73. Taoufik E, Tseveleki V, Euagelidou M, et al. Positive and negative implications of tumor necrosis factor neutralization for the pathogenesis of multiple sclerosis. Neurodegener Dis 2008;5:32-37
74. Sandborn WJ, Hanauer SB, Katz S, et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2001;121:1088-1094
75. Haraoui B. Differentiating the efficacy of the tumor necrosis factor inhibitors. Semin Arthritis Rheum 2005;34:(Suppl 1):7-11
76. Kaymakcalan Z, Sakorafas P, Bose S, et al. Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor. Clin Immunol 2009;131:308-316
77. Fries W, Muja C, Crisafulli C, et al. Infliximab and etanercept are equally effective in reducing enterocyte APOPTOSIS in experimental colitis. Int J Med Sci 2008;5:169-180
78. Suntharalingam G, Perry MR, Ward S, et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 2006;355:1018-1028
79. Schraven B, Kalinke U. CD28 Superagonists: what makes the difference in humans? Immunity 2008;28:591-595
80. St Clair EW. The calm after the cytokine storm: lessons from the TGN1412 trial. J Clin Invest 2008;118:1344-1347
81. Schneider CK, Kalinke U, Löwer J. TGN1412-a regulator's perspective. Nat Biotechnol 2006;24:493-496
82. Muller PY, Brennan FR. Safety assessment and dose selection for first-in-human clinical trials with immunomodulatory monoclonal antibodies. Clin Pharmacol Ther 2009;85:247-258
83. Segal BM, Constantinescu CS, RaychaudhuriA, et al. Repeatedsubcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study. Lancet Neurol 2008;7:796-804
84. Garber K. Immunology's quiet upheaval. Nat Biotech 2009;27:687-689
85. Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006;295:2275-85.
86. Erratum in: JAMA 2006;295:2482
87. Keane J. TNF-blocking agents and tuberculosis: new drugs illuminate an old topic. Rhemuatology 2005;44:714-720
88. Lalvani A, Millington KA. Screening for tuberculosis infection prior to initiation of anti-TNF therapy. Autoimmun Rev 2008;8:147-152
89. Salliot C, Dougados M, Gossec L. Risk of serious infections during rituximab, abatacept and anakinra therapies for rheumatoid arthritis: meta-analyses of randomized placebo-controlled trials. Ann Rheum Dis 2009;68:25-32
90. Calabrese LH, Molloy ES, Huang D, Ransohoff RM. Progressive multifocal leukoencephalopathy in rheumatic diseases: evolving clinical and pathologic patterns of disease. Arthritis Rheum 2007;56:2116-2128
91. Yousry TA, Major EO, Ryschkewitsch C, et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 2006;354:924-933
92. Boren EJ, Cheema GS, Naguwa SM, et al. The emergence of progressive multifocal leukoencephalopathy (PML) in rheumatic diseases. J Autoimmun 2008;30:90-98
93. Molloy ES, Cabrese LH. Progressive multifocal leukoencephalopathy in patients with rheumatic diseases: are patients with systemic lupus erythematosus at particular risk? Autoimmun Rev 2008;8:144-146
94. Setoguchi S, Solomon DH, Weinblatt ME, et al. Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. Arthritis Rheum 2006;54:2757-2764
95. Hauser SL. Multiple lessons for multiple sclerosis. N Engl J Med 2008;359:1838-1841
96. De Jager PL, Hafler DA. New therapeutic approaches for multiple sclerosis. Annu Rev Med 2007;58:417-432
97. Jones JL, Phuah CL, Cox AL, et al. IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). J Clin Invest 2009;119:2052-2061
98. Mohan N, Edwards ET, Cupps TR, et al. Demyelination occurring during anti-TNF-a therapy for inflammatory arthritides. Arthritis Rheum 2001;44:2862-2869
99. Lenercept Multiple Sclerosis Study Group and University of British Columbia MS/ MRI Analysis Group. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology 1999;53:457-465
100. Van Oosten BW, Barkhof F, Truyen L, et al. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 1996;47:1531-1534
101. Aringer M, Smolen JS. Efficacy and safety of TNF-blocker therapy in systemic lupus erythematosus. Expert Opin Drug Saf 2008;7:411-419
102. Aringer M, Graninger WB, Steiner G, Smolen JS. Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study. Arthritis Rheum 2004;50:3161-3169
103. Watier H. Variability factors in the clinical response to recombinant antibodies and IgG Fc-containing fusion proteins. Expert Opin Biol Ther 2005;5:(Suppl 1):S29-36
104. Danila MI, Hughes LB, Bridges SL. Pharmacogenetics of etanercept in rheumatoid arthritis. Pharmacogenomics 2008;9:1011-1015
105. Rokosz LL, Beasley JR, Carroll CD, et al. Kinase inhibitors as drugs for chronic inflammatory and immunological diseases: progress and challenges. Expert Opin Ther Targets 2008;12:883-903
106. McGrogan A, Seaman HE, Wright JW, de Vries CS. The incidence of autoimmune thyroid disease: a systematic review of the literature. Clin Endocrinol (Oxf) 2008;69:687-696
107. Weinblatt ME, Coblyn JS, Fox DA. Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med 1985;312:818-822
108. Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999;130:478-486
109. Lipsky PE, van der Heijde DM, St Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000;343:1594-1602
110. Cohen SB, Moreland LW, Cush JJ. A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. Ann Rheum Dis 2004;63:1062-1068
111. van de Putte LB, Atkins C, Malaise M, et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 2004;63:508-516
112. Genovese MC, Becker JC, Schiff M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 2005;353:1114-23
113. Erratum in: N Engl J Med. 2005;353:2311
114. Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006;54:2793-2806
115. Maini RN, Taylor PC, Szechinski J, et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 2006;54:2817-2829
116. Keystone E, Heijde D, Mason D Jr, et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 2008;58:3319-3329
117. Smolen JS, Kay J, Doyle MK, et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet 2009;374:210-221
118. Saurat JH, Stingl G, Dubertret L, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2008;158:558-566
119. Flytström I, Stenberg B, Svensson A, et al. Methotrexate vs. ciclosporin in psoriasis: effectiveness, quality of life and safety. A randomized controlled trial. Br J Dermatol 2008;158:116-121
120. Lebwohl M, Christophers E, Langley R, et al. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol 2003;139:719-727
121. Gordon KB, Papp KA, Hamilton TK, et al. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA 2003;290:3073-80
122. Erratum in: JAMA 2004;291:1070
123. Papp KA, Tyring S, Lahfa M, et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 2005;152:1304-1312
124. Gottlieb AB, Evans R, Li S, et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 2004;51:534-542
125. Gordon KB, Langley RG, Leonardi C, et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol 2006;55:598-606
126. Krueger GG, Langley RG, Leonardi C, et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 2007;356:580-592
127. Kimball AB, Gordon KB, Langley RG, et al. Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial. Arch Dermatol 2008;144:200-207
128. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. Neurology 1993;43:655-661
129. Jacobsm LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996;39:285-294
130. PRISMS study group. Randomised double-blind placebo-controlled study of interferon b-1a in relapsing/remitting multiple sclerosis. Lancet 1998;352:1498-1504
131. See also: Li DKB, Paty DW, et al. Magnetic resonance imaging results of the PRISMS Trial: a randomized, double-blind, placebo-controlled study of interferon-b1a in relapsing-remitting multiple sclerosis. Ann Neurol 1999;46:197-206
132. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995;45:1268-1276
133. See also: Martinelli BF, Rovaris M, Johnson KP, et al. Effects of glatiramer acetate on relapse rate and accumulated disability in multiple sclerosis: meta analysis of three double-blind, randomized, placebo-controlled clinical trials. Mult Scler 2003;9:349-355
134. Polman CH, O'Connor PW, Harvdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354:899-910
135. Coles AJ, Compston DA, Selmaj KW, et al; CAMMS223 Trial Investigators, Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 2008;359:1786-1801
136. Kappos L, Antel J, Comi G, et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 2006;355:1124-1140
137. Targan SR,Hanauer SB, van DeventerSJH, et al. A short-term study of chimeric monoclonalantibody cA2totumor necrosis factor alpha for Crohn's disease. N Engl J Med 1997;337:1029-1035
138. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359:1541-1549
139. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006;130:323-333
140. Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 2007;56:1232-1239 (Pubitemid 47300424)
141. Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007;357:228-238
142. Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 2007;357:239-250 (Pubitemid 47080388)
143. Sandborn WJ, Colombel JF, Enns R, et al. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 2005;353:1912-1925
144. Feagan BG, Greenberg GR, Wild G, et al. Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin. Clin Gastroenterol Hepatol 2008;6:1370-1377
145. Mannon PJ, Fuss IJ, Mayer L, et al. Anti-interleukin-12 antibody for active Crohn's disease. N Engl J Med 2004;351:2069-2079
146. Sandborn WJ, Feagan BG, Fedorak RN, et al; for the Ustekinumab Crohn's Disease Study Group. A randomized trial of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate to severe Crohn's disease. Gastroenterology 2008;135:1130-1141